[go: up one dir, main page]

JPH06505253A - Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用 - Google Patents

Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用

Info

Publication number
JPH06505253A
JPH06505253A JP4505427A JP50542792A JPH06505253A JP H06505253 A JPH06505253 A JP H06505253A JP 4505427 A JP4505427 A JP 4505427A JP 50542792 A JP50542792 A JP 50542792A JP H06505253 A JPH06505253 A JP H06505253A
Authority
JP
Japan
Prior art keywords
elam
cells
immunoglobulin
antibodies
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4505427A
Other languages
English (en)
Japanese (ja)
Inventor
ウェイナー，エリザベス
フィリップス，メアリー　エル．
ウィンケルヘイク，ジェフリー　エル．
Original Assignee
サイテル　コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイテル　コーポレイション filed Critical サイテル　コーポレイション
Publication of JPH06505253A publication Critical patent/JPH06505253A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP4505427A 1991-01-24 1992-01-23 Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用 Pending JPH06505253A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64587891A 1991-01-24 1991-01-24
US645,878 1991-01-24
US73303391A 1991-07-22 1991-07-22
US733,033 1991-07-22
PCT/US1992/000577 WO1992012729A1 (en) 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses

Publications (1)

Publication Number Publication Date
JPH06505253A true JPH06505253A (ja) 1994-06-16

Family

ID=27094802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4505427A Pending JPH06505253A (ja) 1991-01-24 1992-01-23 Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用

Country Status (11)

Country Link
EP (1) EP0568631A4 (no)
JP (1) JPH06505253A (no)
AU (1) AU1269092A (no)
CA (1) CA2100681A1 (no)
IE (1) IE920206A1 (no)
IL (1) IL100764A0 (no)
NO (1) NO932672L (no)
NZ (1) NZ241399A (no)
OA (1) OA09809A (no)
SK (1) SK77393A3 (no)
WO (1) WO1992012729A1 (no)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012510429A (ja) * 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
WO2019078344A1 (ja) * 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
ATE230614T1 (de) 1998-07-13 2003-01-15 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
CN1356913A (zh) 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP4093508A1 (en) 2020-01-24 2022-11-30 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012510429A (ja) * 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2019078344A1 (ja) * 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Also Published As

Publication number Publication date
EP0568631A1 (en) 1993-11-10
NZ241399A (en) 1994-06-27
WO1992012729A1 (en) 1992-08-06
EP0568631A4 (en) 1995-04-05
NO932672D0 (no) 1993-07-23
CA2100681A1 (en) 1992-07-25
IL100764A0 (en) 1992-09-06
OA09809A (en) 1994-04-15
AU1269092A (en) 1992-08-27
IE920206A1 (en) 1992-07-29
SK77393A3 (en) 1994-12-07
NO932672L (no) 1993-09-23

Similar Documents

Publication Publication Date Title
JPH06505253A (ja) Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用
Russell et al. Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes.
Ross et al. Specificity of membrane complement receptor type three (CR3) for ß-glucans
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
JP2002515235A (ja) 坑アミロイド抗体を用いるアミロイドの除去方法
JP2979318B2 (ja) １７−１ａ抗原に対するモノクローナル抗体による腫瘍の免疫療法
RU2183215C2 (ru) Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего
JPH08505764A (ja) 腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法
JPH06501456A (ja) 表面複合リンホトキシン
CN104284680A (zh) 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
US6245334B1 (en) Method of causing selective immunosuppression using HL-60-related lectins
ES2619313T3 (es) Terapia de anticuerpos monoclonales para el cáncer de páncreas
JP2006504773A (ja) タンパク質性化合物の毒性作用を修飾する組成物および方法
US5643740A (en) Monoclonal antibody specific for activated lymphocytes and monocytes
JPH08501535A (ja) 疾患を治療するためのペプチド薬剤
Mathison et al. Modulation of neutrophil function by the tripeptide feG
Root Leukocyte adhesion proteins: their role in neutrophil function
CA2141598A1 (en) Method of inhibiting cell proliferation using apolipoprotein e
JP3030386B2 (ja) 抗ガン剤
JP3236667B2 (ja) ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
JP2002507967A (ja) 疾病治療のための抗ｃｄ４０ｌイムノトキシン
EP0486609B1 (en) Pharmaceutical product for the treatment of sepsis
CA2095404A1 (en) Purification and characterization of a csvtcg-specific tumor cell adhesion receptor
CA2182215A1 (en) Anti-inflammatory containing monoclonal antibodies having reactivity with sialyl-lewis x sugar chains originating in hemangioendothelial cell membrane
PT100568A (pt) Anticorpos monoclonais e antigeneos para o melanoma humano